How Aromatase Inhibitors Work, Types, and Side Effects

Aromatase inhibitors are a class of drugs that block the body’s production of estrogen by shutting down aromatase, the enzyme responsible for converting androgens into estrogens in tissues like fat, muscle, and skin. They are best known as a frontline hormonal treatment for estrogen-receptor-positive breast cancer in postmenopausal women, where they have largely overtaken tamoxifen as the preferred option. But their reach extends well beyond oncology, with uses in fertility treatment, endometriosis pain management, and even pediatric growth disorders. The story of these drugs is as much about side effects and patient adherence as it is about cancer outcomes, because the same estrogen suppression that starves tumors also quietly weakens bones and inflames joints.

How They Work

Estrogen fuels the growth of most breast cancers. In premenopausal women, the ovaries are the main estrogen factory. After menopause, the ovaries largely shut down, but smaller amounts of estrogen continue to be produced in peripheral tissues when the aromatase enzyme converts circulating androgens into estrogen. Aromatase inhibitors block that conversion, driving estrogen levels down to nearly undetectable levels in postmenopausal women.¹

Steroidal Versus Nonsteroidal Types

Three aromatase inhibitors dominate current clinical use, and they split into two categories based on their chemistry. Anastrozole and letrozole are nonsteroidal. They latch onto the aromatase enzyme reversibly, sitting in the active site and blocking androgens from getting in. If the drug clears from the body, aromatase can resume working. Exemestane, the lone steroidal option, takes a more permanent approach. It mimics the natural substrate that aromatase normally acts on, gets drawn into the enzyme’s active site, and is then converted into a reactive molecule that binds irreversibly. Once exemestane locks in, that particular copy of the enzyme is permanently inactivated.²

Because exemestane is structurally similar to androgens, it may also have mild androgenic effects of its own, though whether that matters clinically remains uncertain.³ In practice, all three drugs are highly selective compared with earlier-generation inhibitors and are effective enough that they have essentially replaced those older agents.⁴

The Case Against Tamoxifen

For decades, tamoxifen was the gold standard for hormonal breast cancer therapy. Aromatase inhibitors have displaced it for postmenopausal women, and the evidence behind that shift is substantial. A large patient-level meta-analysis covering thousands of women found that five years of an aromatase inhibitor, compared with five years of tamoxifen, reduced the recurrence rate during the first several years and lowered ten-year breast cancer mortality from roughly 14% to about 12%. All-cause mortality also fell.⁵ An earlier meta-analysis of adjuvant trials showed a consistent pattern: aromatase inhibitors produced an absolute decrease in recurrence of about 3 percentage points at five years whether used from the start or after an initial stretch of tamoxifen.⁶

The trade-off is specific. Aromatase inhibitors caused fewer endometrial cancers than tamoxifen, which has estrogen-like effects on the uterine lining. But bone fractures were clearly more common with aromatase inhibitors, a theme that runs through nearly every side-effect discussion about these drugs.⁷

Premenopausal Women and Ovarian Suppression

Aromatase inhibitors alone do not work well in premenopausal women because the ovaries simply ramp up estrogen production to compensate for what the drug blocks in peripheral tissues. To use an aromatase inhibitor before menopause, the ovaries must first be suppressed, either with drugs that shut down the hormonal signal telling the ovaries to produce estrogen, or through surgical removal. When that ovarian suppression is in place, combining it with an aromatase inhibitor has been shown to outperform the older combination of tamoxifen plus ovarian suppression.

A patient-level meta-analysis of more than 7,000 premenopausal women found that adding an aromatase inhibitor to ovarian suppression reduced the rate of breast cancer recurrence compared with tamoxifen plus ovarian suppression. The five-year recurrence rate dropped from about 10% to about 7%. However, with a median follow-up of eight years, no significant difference in breast cancer mortality or overall survival had emerged.⁸ That gap between fewer recurrences and no clear survival advantage remains an active question in the field. Earlier combined trial data showed disease-free survival of about 91% with exemestane plus ovarian suppression versus about 87% with tamoxifen plus ovarian suppression after roughly five and a half years of follow-up.⁹

How Long to Take Them

The standard course is five years of hormonal therapy, but whether extending treatment further improves outcomes has been one of the more contested questions in breast cancer care. The answer appears to depend on the clinical scenario. In one landmark trial, women who had already completed five years of tamoxifen followed by five years of an aromatase inhibitor were randomized to either stop or continue the aromatase inhibitor for an additional five years. Extending to a total of ten years of hormonal therapy (with the aromatase inhibitor portion going from five to ten) showed a disease-free survival benefit and cut the rate of new cancers in the opposite breast roughly in half. But overall survival did not differ, and bone-related side effects were more common in the group that continued treatment.¹⁰

Other trials have been less enthusiastic. A large Dutch trial found no significant disease-free survival advantage from six years of anastrozole versus three years after prior tamoxifen, and the longer group had more joint pain and bone thinning.¹¹ And a trial comparing a five-year extension of aromatase inhibitor therapy to a two-year extension found no benefit at all from the longer course, only more fractures.¹² The emerging picture is that extending treatment may help a specific subset of higher-risk patients, but blanket extension for all women adds side effects without clear gains.

Bone Loss and Fracture Risk

Estrogen protects bones. When aromatase inhibitors strip postmenopausal women of their remaining estrogen, bone mineral density drops and fracture risk climbs. This is not subtle: in the large meta-analysis comparing aromatase inhibitors with tamoxifen, the five-year fracture risk was about 8% with aromatase inhibitors versus roughly 5.5% with tamoxifen.¹³ All three aromatase inhibitors are associated with this skeletal toll.¹⁴

Guidelines generally recommend bone density screening before or shortly after starting an aromatase inhibitor, along with calcium and vitamin D supplementation. Women at higher fracture risk may receive bisphosphonates or denosumab to counteract bone loss. The bone issue is worth taking seriously not just because fractures hurt, but because it is one of the major drivers pushing patients to quit treatment early.

Joint Pain and the Adherence Problem

If bone loss is the slow-burning side effect, joint pain is the one patients feel daily. Aromatase inhibitor-associated musculoskeletal syndrome is the umbrella term for the stiffness, aching, and sometimes debilitating joint pain that can develop within weeks to months of starting treatment. Roughly half of women on aromatase inhibitor therapy report new or worsening joint pain during the first year.¹⁵ The mechanism is not fully understood but is thought to stem from estrogen depletion in the joints and nervous system.¹⁶

This pain is the single biggest reason women stop their aromatase inhibitor early. About 30% of patients discontinue within the first year, and only about half to two-thirds remain fully compliant after three years.¹⁷ Worsening musculoskeletal symptoms are the strongest predictor of early discontinuation, more so than mood changes, cognitive complaints, or weight gain.¹⁸ Sleep quality also plays a role: women who report poor sleep before starting treatment are about twice as likely to discontinue.¹⁹

Switching between aromatase inhibitors sometimes helps. A patient who cannot tolerate anastrozole might do better on exemestane, or vice versa. Exercise, particularly moderate resistance and aerobic training, has shown promise in reducing joint symptoms, and acupuncture has been studied with mixed results. The core challenge is that the drug works by eliminating estrogen, and estrogen depletion is what causes the pain, so there is no clean pharmacological fix that preserves the cancer benefit.

Cardiovascular and Metabolic Effects

Tamoxifen, for all its other drawbacks, has mildly favorable effects on cholesterol. Aromatase inhibitors do not share that perk. The cardiovascular picture with aromatase inhibitors is more complicated and still being sorted out. A population-based cohort study found that aromatase inhibitor use was associated with a higher rate of heart failure and cardiovascular death compared with tamoxifen, though the risks of heart attack and stroke were elevated without reaching statistical significance.²⁰

The three drugs may not behave identically here. Available data suggest anastrozole has relatively little effect on lipid levels in some studies but adverse effects in others. Letrozole has been linked to unfavorable lipid shifts. Exemestane, interestingly, may be slightly kinder to cholesterol profiles, possibly because of its weak androgenic properties.²¹ A systematic review and meta-analysis of lipid changes found that letrozole and exemestane at certain timepoints tended to push lipid profiles in an undesirable direction, while anastrozole and tamoxifen did not show the same pattern.²² For patients with pre-existing heart disease or significant cardiovascular risk factors, this is a conversation worth having with an oncologist, particularly since tamoxifen remains an alternative.

Cognitive Effects

Some women on aromatase inhibitors report brain fog, forgetfulness, or difficulty concentrating. The research here tells a mixed story. One longitudinal study of women taking anastrozole found measurable dips in working memory and concentration during the first six months of treatment, with partial recovery and then a second decline around the 12-to-18-month mark.²³ But a randomized, placebo-controlled chemoprevention trial found no significant differences in cognitive performance between women on anastrozole and those on placebo, though more women on anastrozole reported hot flashes.²⁴ The discrepancy may partly reflect the difficulty of separating drug effects from the broader cognitive impact of a cancer diagnosis, stress, and aging. Still, cognitive complaints contribute to treatment discontinuation, and dismissing them does patients no favors.

When Resistance Develops

In early-stage disease, aromatase inhibitors significantly reduce the risk of recurrence. But in advanced or metastatic breast cancer, resistance is essentially inevitable. Cancer cells find ways to grow despite near-zero estrogen levels. The mechanisms are diverse and can include mutations in the estrogen receptor itself, activation of alternative growth pathways that bypass the need for estrogen signaling, and changes in the tumor’s genomic landscape that reactivate cell proliferation.²⁵

This has spurred research into combination strategies. CDK4/6 inhibitors like palbociclib and ribociclib are now commonly paired with aromatase inhibitors or other hormonal therapies in advanced disease. Laboratory work has also explored co-targeting CDK2 alongside CDK4/6 to overcome resistance that develops even to those newer drugs, with early preclinical results showing that triple combination approaches can arrest cell growth and trigger cell death in resistant tumor models.²⁶

Fertility Treatment

Beyond cancer, aromatase inhibitors have carved out a significant role in reproductive medicine. Letrozole is now widely used to induce ovulation in women with polycystic ovary syndrome who are trying to conceive. In a major multicenter trial, women given letrozole had a cumulative live birth rate of about 28%, compared with roughly 19% for those given clomiphene, the traditional first-line ovulation drug. Letrozole also produced a higher ovulation rate per treatment cycle.²⁷ A smaller trial confirmed the direction of those results, showing a meaningfully higher pregnancy and live birth rate with letrozole while also producing more single-follicle development, which means a lower risk of twins.²⁸

The logic is straightforward: by temporarily blocking estrogen production, letrozole tricks the brain into thinking estrogen is too low, prompting the pituitary gland to release more of the hormones that stimulate the ovaries to develop and release an egg. Because the drug is short-acting and cleared quickly, the estrogen blockade lifts after the medication is stopped, allowing the uterine lining to thicken normally for embryo implantation.

Endometriosis Pain

Endometriosis lesions produce their own estrogen via local aromatase activity, which is one reason the disease can be so stubborn. Aromatase inhibitors address this by cutting off that local estrogen supply. Systematic reviews have found that aromatase inhibitors combined with progestogens or oral contraceptives reduce pain severity and improve quality of life in women with endometriosis.²⁹ When combined with GnRH analogues, aromatase inhibitors produced significantly greater pain improvement than GnRH analogues alone.³⁰ This use is not as mainstream as the cancer or fertility indications, but for women with severe, refractory endometriosis pain, it represents an option when standard hormonal therapies have failed.

Uses in Males

Men produce small amounts of estrogen too, and aromatase inhibitors have been explored in several male-specific contexts. In boys with short stature or delayed puberty, the idea is that blocking estrogen slows the closure of growth plates in the bones, potentially allowing more time for growth. Short-term data from trials have generally shown improvements in predicted adult height, but a Cochrane review found limited evidence that these predicted gains translate into actual final adult height, with only one of four trials publishing final height data.³¹ More recent work combining aromatase inhibitors with growth hormone in adolescent males with idiopathic short stature has shown more promising results for final height, with anastrozole appearing to produce better outcomes and fewer side effects than letrozole in that context.³²

In older men with low testosterone, aromatase inhibitors can raise testosterone levels by reducing its conversion to estrogen, but long-term evidence of benefit is lacking.³³ This hasn’t stopped widespread off-label use, particularly among men on testosterone replacement therapy who develop elevated estrogen levels.

Misuse in Bodybuilding

Aromatase inhibitors have a substantial underground following among men who use anabolic steroids. When someone injects supraphysiological doses of testosterone or similar compounds, the body converts a portion of that excess into estrogen, which can cause breast tissue growth, water retention, and other unwanted effects. Aromatase inhibitors are used to counteract that conversion. An analysis of nearly 1,800 posts on an online steroid forum found that aromatase inhibitors accounted for a large share of ancillary drug discussions. The users were exclusively male, averaging about 28 years old, with typical treatment durations of around 70 days for anastrozole and 84 days for exemestane. Adverse reactions reported included acne, musculoskeletal complaints, mood disturbances, and reproductive problems, with about a quarter of users describing impaired quality of life.³⁴ Most obtained these prescription drugs through the internet without medical supervision, raising concerns about inappropriate dosing and unmonitored bone and cardiovascular health.

Genetic Variation in Drug Response

Not everyone responds to aromatase inhibitors the same way, and part of the variability may be written into the gene that codes for the aromatase enzyme itself, CYP19A1. One study identified specific genetic variants upstream of a key region of the gene that were associated with greater inhibition of aromatase activity during treatment, meaning women carrying those variants got more out of the drug.³⁵ However, when another group of researchers looked at whether CYP19A1 variants predicted how long aromatase inhibitors kept metastatic disease under control, the results were less encouraging. Some variants showed initial associations with time to treatment failure, but these did not hold up in analyses that accounted for other prognostic factors like tumor grade and the number of disease sites.³⁶ Pharmacogenomic testing for aromatase inhibitor response is not part of routine practice, though research continues. The field is a good reminder that finding a statistically interesting genetic signal is not the same as finding one that changes treatment decisions.

Cost and Coverage

All three major aromatase inhibitors are available as generics, which has dramatically reduced their cost since they first came to market. From a health-economics perspective, aromatase inhibitors have generally been found cost-effective compared with tamoxifen. A systematic review of published cost-effectiveness analyses found that the cost per quality-adjusted life year for aromatase inhibitors versus tamoxifen fell below widely used willingness-to-pay thresholds in the large majority of studies, regardless of which specific aromatase inhibitor was being compared.³⁷ One modeling study found that providing full prescription coverage for aromatase inhibitors to Medicare beneficiaries with early breast cancer would actually save money overall while slightly improving quality-adjusted survival, because better adherence to therapy reduces the downstream costs of cancer recurrence.³⁸ That finding underscores how tightly adherence and outcomes are linked: the drugs only work if patients keep taking them, and out-of-pocket costs are one more barrier on top of the side effects already pushing people to quit.